Tag: Skin Cancer

Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/{alpha}PD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING

Localized radiotherapy (RT) can cause a T cell-mediated abscopal effect on non-irradiated tumor lesions, especially in combination with immune checkpoint blockade . We investigated whether a low dose of liposomal doxorubicin (Doxil) and RT/αPD-1 could augment a clinical improvement .

Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade

Background BANF1 is well known as a natural opponent of cyclic GMP-AMP synthase (cGAS) activity on genomic self-DNA. However, the roles of BANF1 in tumor immunity remain unclear. Here, we investigate the possible impact of BANF1 on antitumor immunity and response to immunotherapy. Methods The Cancer Genome Atlas public data were analyzed to evaluate the… Continue reading Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade

Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer

Cisplatin-based chemotherapy has been associated with durable disease control in a small subset of patients with metastatic urothelial cancer. However, the mechanistic basis for this phenomenon has remained elusive. Antitumor immunity may underlie these exceptional responders. In a phase II trial evaluating a phased schedule of gemcitabine and cisplatin followed by gemcitabine and cisplatin with… Continue reading Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer

Different prognostic values of KRAS exon 2 sub-mutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of 7 trials.

The prognostic value of KRAS and BRAFV600E mutations in stage III CC remains controversial and has never been clearly analyzed in patients with MSI-H tumors due to sample size limitations . Data are also lacking for

Moving the needle on monitoring skin cancer

A research team has developed a new approach that integrates a minimally invasive, painless microneedle platform capable of absorbing the cell-surrounding, biomarker-containing fluid from deeper layers of the skin with an ultra-sensitive, single-molecule detection method (Simoa) that detects often rare, yet relevant biomarkers with higher sensitivity than conventional methods.

TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV-associated oral squamous cell carcinoma

Background TP53, the most mutated gene in solid cancers, has a profound impact on most hallmarks of cancer. Somatic TP53 mutations occur in high frequencies in head and neck cancers, including oral squamous cell carcinoma (OSCC). Our study aims to understand the role of TP53 gain-of-function mutation in modulating the tumor immune microenvironment (TIME) in… Continue reading TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV-associated oral squamous cell carcinoma

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy

B-cells and T-cell receptor (BCR, TCR) repertoire affects the tumor immune microenvironment (TIME) and clinical outcomes in patients treated with immunotherapy . BCR diversity was more associated with antibody responses but not with the overall B cell infiltration, nor with measures related to intratumoral CD8+T cell activity .